Guiyang Xintian Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sales of Chinese patent drugs. The Company manufactures its products in the forms of capsules, mixture, granules, syrup, gel and tablets. The Companyâ€™s main products include Ningmitai Capsule, Kuntai Capsule, Kushen Gel and Xiaokucao Oral Liquid .The Company distributes its products in the domestic market.

Employees

1,388

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-17	CN¥7.890	-6.41%	13,255,200
26-07-16	CN¥8.430	+3.18%	12,499,730
26-07-15	CN¥8.170	+3.16%	10,654,260
26-07-14	CN¥7.920	+2.86%	9,641,400
26-07-13	CN¥7.700	+0.26%	9,946,594

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2026-07-17			5-day change	1st Jan Change
7.890 ^CNY	-6.41%		+2.73%	-20.46%

05-07	Guiyang Xintian says key shareholder plans to unload up to about 3% stake	RE
04-29	Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	1.86B 274M 239M 221M 204M 384M 26.38B 392M 2.64B 1.04B 12.92B 1.03B 1.01B 44.47B	P/E 2024	39.9x	P/E 2025	256x
Enterprise Value	2.35B 347M 303M 280M 258M 486M 33.41B 497M 3.34B 1.32B 16.36B 1.3B 1.27B 56.33B	EV / Sales 2024	3.07x	EV / Sales 2025	3.77x
Free-Float	62.08%	Yield 2024	1.06%	Yield 2025	0.3%

05-07	Guiyang Xintian says key shareholder plans to unload up to about 3% stake	RE
04-29	Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-03	Guiyang Xintian Pharmaceutical to Offload Up to 2.4 Million Repurchased Shares	MT
03-30	Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	Guiyang Xintian Pharmaceutical Co.,Ltd. announces Annual dividend, payable on May 27, 2026	CI
03-26	Guiyang Xintian Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 300 million in funding	CI
25-10-30	Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-20	Xintian Pharma's controlling shareholder to cut stake	RE
25-10-15	Guiyang Xintian Pharmaceutical Gets China Clinical Trial Nod for Traditional Chemotherapy Supplemental Drug	MT
25-09-17	Guiyang Xintian Pharmaceutical Co.,Ltd. agreed to acquire an additional minority stake in Shanghai Huilun Life Sciences & Technology Co., Ltd. from Hubei Pinghu Venture Capital Co., Ltd. for CNY 20 million.	CI
25-09-17	Shanghai Huilun Life Sciences & Technology Co., Ltd. announced that it has received CNY 72 million in funding from Guiyang Xintian Pharmaceutical Co.,Ltd.	CI
25-09-04	Xintian Pharmaceutical Completes Setting Up Subsidiary	MT
25-08-20	Shanghai Huilun Life Sciences & Technology Co., Ltd. announced that it expects to receive CNY 72 million in funding from Guiyang Xintian Pharmaceutical Co.,Ltd. and other investors	CI

1 day	-6.41%
1 week	+2.73%
Current month	+7.79%
1 month	+1.81%
3 months	-18.07%
6 months	-22.65%
Current year	-20.46%

Guiyang Xintian Pharmaceutical Co.,Ltd. Stock

Stocks

002873

CNE100002QB5

Pharmaceuticals

Valuation: Guiyang Xintian Pharmaceutical Co.,Ltd.

Chart: Guiyang Xintian Pharmaceutical Co.,Ltd.

Latest news : Guiyang Xintian Pharmaceutical Co.,Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Guiyang Xintian Pharmaceutical Co.,Ltd.

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	7.53	8.51
1 month	7.04	8.51
Current year	7.04	13.09
1 year	7.04	15.19
3 years	7.04	15.19
5 years	7.04	20.12
10 years	6.63	20.12

Manager	Title	Age	Since
Da Lun Dong CEO	Chief Executive Officer	62	1995-08-10
Zhi Hui Zeng DFI	Director of Finance/CFO	53	2019-11-03
Zhong Lei He PRN	Corporate Officer/Principal	49	2021-03-31

Director	Title	Age	Since
Da Lun Dong CHM	Chairman	62	1995-08-10
Jin Hua Wang BRD	Director/Board Member	59	1995-08-10
Wen Yi Wang BRD	Director/Board Member	53	2013-04-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIYANG XINTIAN PHARMACEUTICAL CO.,LTD.	-6.41%	+2.73%	-24.43%	-36.73%	274M
MERCK & CO., INC.	-0.10%	+3.21%	+59.45%	+20.34%	315B
MERCK KGAA	-1.20%	-2.43%	+23.24%	-8.31%	67.81B
HALOZYME THERAPEUTICS, INC.	+0.35%	+2.11%	+37.84%	+86.59%	9.23B
KYOWA KIRIN CO., LTD.	+0.34%	+0.51%	+5.21%	-0.69%	8.56B
SK BIOPHARMACEUTICALS CO., LTD.	+1.53%	-3.64%	-22.91%	+5.31%	4.18B
BETTA PHARMACEUTICALS CO., LTD.	-11.03%	-12.07%	-8.02%	+14.00%	3.59B
YUHAN CORPORATION	+1.87%	+3.36%	-46.36%	+28.62%	3.55B
SUPERNUS PHARMACEUTICALS, INC.	-0.35%	-0.87%	+48.55%	+60.56%	2.79B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-7.41%	-2.37%	+3.91%	-23.64%	2.09B
Average	-2.24%	-1.30%	+7.65%	+14.60%	41.7B
Weighted average by Cap.	-0.36%	+1.02%	+49.26%	+16.59%

	2024	2025
Net sales	858M 127M 111M 102M 94.04M 177M 12.18B 181M 1.22B 480M 5.97B 475M 465M 20.54B	750M 111M 96.66M 89.2M 82.22M 155M 10.65B 158M 1.07B 419M 5.22B 415M 406M 17.96B
Net income	52.32M 7.72M 6.75M 6.22M 5.74M 10.81M 743M 11.05M 74.4M 29.26M 364M 28.99M 28.35M 1.25B	9.11M 1.34M 1.17M 1.08M 999K 1.88M 129M 1.93M 12.96M 5.1M 63.4M 5.05M 4.94M 218M
Net Debt	442M 65.19M 56.97M 52.57M 48.46M 91.34M 6.28B 93.36M 628M 247M 3.07B 245M 239M 10.59B	495M 73.04M 63.83M 58.9M 54.29M 102M 7.03B 105M 704M 277M 3.44B 274M 268M 11.86B